SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...

BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System ...

Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...

TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority ...

Synthetic bio company Asimov agreed to collaborate with Cytiva to provide customers with an integrated offering for optimized biologics production. Access includes Asimov’s CHO Edge cell line ...

This partnership provides the industry with cutting-edge options for mammalian-expressed products. OKLAHOMA CITY & MONTHEY, Switzerland--(BUSINESS WIRE)--ExcellGene SA, a leading Swiss biotech service ...

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and ...

Advances in cell line engineering and microfluidic technologies offer substantial opportunities to shorten timelines in cell line development (CLD). However, as with any innovation, optimizing these ...